DPP4/CD26 Proteins, Antibodies, cDNA Clones Research Reagents

All DPP4/CD26 reagents are produced in house and quality controlled, including 14 DPP4/CD26 Antibody, 41 DPP4/CD26 Gene, 8 DPP4/CD26 Lysate, 8 DPP4/CD26 Protein, 2 DPP4/CD26 qPCR. All DPP4/CD26 reagents are ready to use.

DPP4/CD26 Protein (8)

    DPP4/CD26 Antibody (14)

      DPP4/CD26 cDNA Clone (41)

      NM_001935.3

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_001159543.1

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_012789.1

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_001039190.1

      克隆载体 cDNA 产品

      In lentiviral vector

      DPP4/CD26 Lysate (8)

        DPP4/CD26 分子背景

        Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.

        DPP4/CD26 参考文献

        • Doupis J, et al. (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 25(7): 627-43.
        • Havre PA, et al. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 13: 1634-45.
        • De Chiara L, et al. (2009) Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers. 7(6): 311-6.
        • Matteucci E, et al. (2009) Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 16(23): 2943-51.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.